BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 25996952)

  • 1. Identification of the Adapter Molecule MTSS1 as a Potential Oncogene-Specific Tumor Suppressor in Acute Myeloid Leukemia.
    Schemionek M; Kharabi Masouleh B; Klaile Y; Krug U; Hebestreit K; Schubert C; Dugas M; Büchner T; Wörmann B; Hiddemann W; Berdel WE; Brümmendorf TH; Müller-Tidow C; Koschmieder S
    PLoS One; 2015; 10(5):e0125783. PubMed ID: 25996952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AML1-ETO triggers epigenetic activation of early growth response gene l, inducing apoptosis in t(8;21) acute myeloid leukemia.
    Fu L; Huang W; Jing Y; Jiang M; Zhao Y; Shi J; Huang S; Xue X; Zhang Q; Tang J; Dou L; Wang L; Nervi C; Li Y; Yu L
    FEBS J; 2014 Feb; 281(4):1123-31. PubMed ID: 24314118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FLT3-TKD mutation in childhood acute myeloid leukemia.
    Liang DC; Shih LY; Hung IJ; Yang CP; Chen SH; Jaing TH; Liu HC; Wang LY; Chang WH
    Leukemia; 2003 May; 17(5):883-6. PubMed ID: 12750701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Haematological & molecular profile of acute myelogenous leukaemia in India.
    Sazawal S; Kumar B; Hasan SK; Dutta P; Kumar R; Chaubey R; Mir R; Saxena R
    Indian J Med Res; 2009 Mar; 129(3):256-61. PubMed ID: 19491417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study.
    Lucena-Araujo AR; Kim HT; Jacomo RH; Melo RA; Bittencourt R; Pasquini R; Pagnano K; Fagundes EM; Chauffaille Mde L; Chiattone CS; Lima AS; Ruiz-Argüelles G; Undurraga MS; Martinez L; Kwaan HC; Gallagher R; Niemeyer CM; Schrier SL; Tallman MS; Grimwade D; Ganser A; Berliner N; Ribeiro RC; Lo-Coco F; Löwenberg B; Sanz MA; Rego EM
    Ann Hematol; 2014 Dec; 93(12):2001-10. PubMed ID: 24981688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical significance of lymphoid enhancer-binding factor 1 expression in acute myeloid leukemia.
    Fu Y; Zhu H; Wu W; Xu J; Chen T; Xu B; Qian S; Li J; Liu P
    Leuk Lymphoma; 2014 Feb; 55(2):371-7. PubMed ID: 23713453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PML-RARalpha and AML1-ETO translocations are rarely associated with methylation of the RARbeta2 promoter.
    Tabe Y; Konopleva M; Kondo Y; Contractor R; Jin L; Ruvolo V; Tsutsumi-Ishii Y; Miyake K; Miyake N; Ohsaka A; Nagaoka I; Issa JP; Andreeff M
    Ann Hematol; 2006 Oct; 85(10):689-704. PubMed ID: 16832676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [FLT3 gene overexpression and its clinical significance in acute myeloid leukemia with AML1/ETO fusion gene positive].
    Xie HM; Gao L; Wang N; Xu YY; Shi JL; Yu L; Wang LL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Oct; 22(5):1199-205. PubMed ID: 25338557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk assessment in patients with acute myeloid leukemia and a normal karyotype.
    Bienz M; Ludwig M; Leibundgut EO; Mueller BU; Ratschiller D; Solenthaler M; Fey MF; Pabst T
    Clin Cancer Res; 2005 Feb; 11(4):1416-24. PubMed ID: 15746041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AML1-ETO targets and suppresses cathepsin G, a serine protease, which is able to degrade AML1-ETO in t(8;21) acute myeloid leukemia.
    Jin W; Wu K; Li YZ; Yang WT; Zou B; Zhang F; Zhang J; Wang KK
    Oncogene; 2013 Apr; 32(15):1978-87. PubMed ID: 22641217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The AML1-ETO fusion gene and the FLT3 length mutation collaborate in inducing acute leukemia in mice.
    Schessl C; Rawat VP; Cusan M; Deshpande A; Kohl TM; Rosten PM; Spiekermann K; Humphries RK; Schnittger S; Kern W; Hiddemann W; Quintanilla-Martinez L; Bohlander SK; Feuring-Buske M; Buske C
    J Clin Invest; 2005 Aug; 115(8):2159-68. PubMed ID: 16025155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Downregulation of MTSS1 in acute myeloid leukemia is associated with a poor prognosis, chemotherapy resistance, and disease aggressiveness.
    Grandits AM; Nguyen CH; Schlerka A; Hackl H; Sill H; Etzler J; Heyes E; Stoiber D; Grebien F; Heller G; Wieser R
    Leukemia; 2021 Oct; 35(10):2827-2839. PubMed ID: 33782537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The fusion protein AML1-ETO in acute myeloid leukemia with translocation t(8;21) induces c-jun protein expression via the proximal AP-1 site of the c-jun promoter in an indirect, JNK-dependent manner.
    Elsässer A; Franzen M; Kohlmann A; Weisser M; Schnittger S; Schoch C; Reddy VA; Burel S; Zhang DE; Ueffing M; Tenen DG; Hiddemann W; Behre G
    Oncogene; 2003 Aug; 22(36):5646-57. PubMed ID: 12944913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [THE CLINICAL SIGNIFICANCE OF GENETIC MUTATIONS IN ACUTE MYELOID LEUKEMIA].
    Goryainova NV
    Lik Sprava; 2014 Dec; (12):10-8. PubMed ID: 26638462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias.
    Lo Coco F; Pisegna S; Diverio D
    Haematologica; 1997; 82(3):364-70. PubMed ID: 9234595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Constitutive activation of Flt3 and STAT5A enhances self-renewal and alters differentiation of hematopoietic stem cells.
    Moore MA; Dorn DC; Schuringa JJ; Chung KY; Morrone G
    Exp Hematol; 2007 Apr; 35(4 Suppl 1):105-16. PubMed ID: 17379095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MTSS1, a novel target of DNA methyltransferase 3B, functions as a tumor suppressor in hepatocellular carcinoma.
    Fan H; Chen L; Zhang F; Quan Y; Su X; Qiu X; Zhao Z; Kong KL; Dong S; Song Y; Chan TH; Guan XY
    Oncogene; 2012 May; 31(18):2298-308. PubMed ID: 21909138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repression of vascular endothelial growth factor expression by the runt-related transcription factor 1 in acute myeloid leukemia.
    Ter Elst A; Ma B; Scherpen FJ; de Jonge HJ; Douwes J; Wierenga AT; Schuringa JJ; Kamps WA; de Bont ES
    Cancer Res; 2011 Apr; 71(7):2761-71. PubMed ID: 21447743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute promyelocytic leukemia relapsing as secondary acute myelogenous leukemia with translocation t(3;21)(q26;q22) and RUNX1-MDS1-EVI1 fusion transcript.
    Park TS; Choi JR; Yoon SH; Song J; Kim J; Kim SJ; Kwon O; Min YH
    Cancer Genet Cytogenet; 2008 Dec; 187(2):61-73. PubMed ID: 19027486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. miR-155 regulative network in FLT3 mutated acute myeloid leukemia.
    Salemi D; Cammarata G; Agueli C; Augugliaro L; Corrado C; Bica MG; Raimondo S; Marfia A; Randazzo V; Dragotto P; Di Raimondo F; Alessandro R; Fabbiano F; Santoro A
    Leuk Res; 2015 Aug; 39(8):883-96. PubMed ID: 26055960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.